CINCINNATI – Onconetix, a publicly traded biotechnology firm based in downtown Cincinnati, has announced the appointment of David White as its new Chief Executive Officer, marking a significant leadership change within the company. This announcement, made effective from March 18, follows a period of considerable transition, as White is the fifth individual to assume the CEO position within a span of two years.
White takes over the role from Karina Fedasz, who served as the interim CEO since April 2025. Fedasz stepped into the position following a series of leadership departures that left the company seeking stability at the highest levels of management. In addition to her interim CEO duties, she will continue her role as the interim Chief Financial Officer.
Onconetix focuses on advancing healthcare solutions related to men’s health and oncology, sectors that are increasingly gaining attention within the biotechnology field. As the company moves forward under new leadership, stakeholders will be keen to observe how these changes will influence its strategic direction and operational effectiveness.
For those interested in learning more about funding opportunities in the biotechnology sector, resources are available through various initiatives aimed at fostering innovation and responsible research practices.
For further details, please refer to the original coverage by the Cincinnati Business Courier.